Quality standard
Update information
Update information
September 2015: This quality standard has been updated to ensure alignment with NICE's quality standard for cardiovascular risk assessment and lipid modification published in September 2015.
Statement 3 on statin therapy has been removed and replaced by statements in NICE's quality standard for cardiovascular risk assessment and lipid modification that cover primary and secondary prevention of cardiovascular disease.
Minor changes since publication
March 2024: Data sources have been reviewed and references to national data sources added to measures in statements 1, 4 and 5. Statements 1 and 4 have been amended to reflect the use of ambulatory blood pressure monitoring and home blood pressure monitoring. Structure measures have been removed.
December 2023: Changes have been made to align this quality standard with the updated NICE guideline on cardiovascular disease: risk assessment and reduction, including lipid modification. The definition for review of risk factors for cardiovascular disease has been updated in statement 5.
May 2023: Changes have been made to align this quality standard with the updated NICE guideline on cardiovascular disease: risk assessment and reduction, including lipid modification. Source guidance references have been updated for a definition used in quality statement 5.
March 2022: Changes have been made to align this quality standard with the updated NICE guideline on hypertension in adults. Source guidance references have been updated throughout.
August 2019: Changes have been made to align this quality standard with the updated NICE guideline on hypertension in adults. Links, definitions and source guidance references have been updated throughout.